ABSTRACT

Introduction

The type 1 interferon pathway is known to play a role in the immunopathology of systemic lupus erythematosus (SLE). As a result, biologic agents targeting this pathway have been developed and are currently being investigated in clinical trials.

Areas covered

We review the biologic agents which have been developed to antagonize type I interferons in SLE. We focus on anifrolumab, a type I interferon receptor antagonist, and consider the complexities of defining efficacy in SLE clinical trials.

Expert opinion

Anifrolumab shows promise as an addition to the SLE therapeutic armamentarium. Despite discordant results between its two phase III studies, there is a convincing suggestion of benefit in both trials to encourage the view that this approach might be effective. Data acquired thus far look particularly useful for cutaneous disease. We await data on its effect on renal, pulmonary, cardiac, and central nervous system involvement, on patient reported outcomes, and its safety and efficacy with long-term use.

中文翻译：

---

用于治疗系统性红斑狼疮的抗干扰素αR单克隆抗体

摘要

介绍

已知 1 型干扰素途径在系统性红斑狼疮 (SLE) 的免疫病理学中起作用。因此，已经开发出靶向该途径的生物制剂，目前正在临床试验中进行研究。

覆盖区域

我们回顾了已开发用于拮抗 SLE 中 I 型干扰素的生物制剂。我们专注于 anifrolumab，一种 I 型干扰素受体拮抗剂，并考虑在 SLE 临床试验中定义疗效的复杂性。

专家意见

Anifrolumab 有望成为 SLE 治疗设备的补充。尽管其两项 III 期研究的结果不一致，但两项试验都有令人信服的获益建议，以鼓励这种方法可能有效的观点。迄今为止获得的数据看起来对皮肤疾病特别有用。我们等待有关其对肾、肺、心脏和中枢神经系统受累的影响、患者报告的结果以及长期使用的安全性和有效性的数据。